No information is available on the clinical use of enasidenib during breastfeeding. Because enasidenib is 98.5% bound to plasma proteins and its active metabolite is 96.6% bound to plasma proteins, the amount in milk is likely to be low. However, the half-life of enasidenib is 137 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during enasidenib therapy and for at least 2 months after the end of therapy.
关于母乳喂养期间使用恩杂鲁胺的临床信息尚无可用资料。由于恩杂鲁胺与血浆蛋白的结合率为98.5%，其活性代谢物与血浆蛋白的结合率为96.6%，因此乳汁中的含量可能较低。然而，恩杂鲁胺的半衰期为137小时，可能会在婴儿体内蓄积。制造商建议在恩杂鲁胺治疗期间及治疗结束后至少2个月内停止母乳喂养。
